NASDAQ: SMMTSummit Therapeutics Inc Stock
$19.89-0.35 (-1.73%)
Updated Mar 26, 2025
SMMT Price
$19.89
Fair Value Price
$0.18
Market Cap
$14.67B
52 Week Low
$2.10
52 Week High
$33.89
P/E
-6,630x
P/B
37.74x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$221.32M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.12
Operating Cash Flow
-$142M
Beta
0.52
Next Earnings
Apr 29, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SMMT Overview
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SMMT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SMMT
Ranked#180 of 479
Ranked#180 of 479
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.48 | A | |
| $8.52 | A | |
| $130.88 | A |
Be the first to know about important SMMT news, forecast changes, insider trades & much more!
SMMT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SMMT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SMMT ($19.89) is overvalued by 11,236.95% relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SMMT ($19.89) is not significantly undervalued (11,236.95%) relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SMMT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SMMT due diligence checks available for Premium users.
Valuation
SMMT fair value
Fair Value of SMMT stock based on Discounted Cash Flow (DCF)
Price
$19.89
Fair Value
$0.18
Overvalued by
11,236.95%
SMMT ($19.89) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SMMT ($19.89) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SMMT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SMMT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6,630x
Industry
-115.59x
Market
31.65x
SMMT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
37.74x
Industry
4.53x
SMMT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SMMT's financial health
Profit margin
Revenue
$0.0
Net Income
-$61.2M
Profit Margin
0%
SMMT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$435.6M
Liabilities
$46.8M
Debt to equity
0.12
SMMT's short-term assets ($423.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SMMT's short-term assets ($423.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SMMT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SMMT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$48.7M
Investing
$83.5M
Financing
-$23.6M
SMMT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SMMT vs Biotech Stocks
Summit Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.